Trial Profile
A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naive Metastatic Kidney Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Biomarker; Proof of concept; Therapeutic Use
- Acronyms BIONIKK
- 18 Feb 2023 Results assessing efficacy results of the second-line (L2) treatment, presented at the 2023 Genitourinary Cancers Symposium.
- 13 Sep 2022 Results identifying biomarkers of N+/-I efficacy in a comprehensive translational research program characterizing in-situ immune markers in frontline metastatic clear cell renal cell carcinoma .presented at the 47th European Society for Medical Oncology Congress
- 04 Apr 2022 Results published in the Lancet Oncology